- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01638780
Resveratrol and Type 2 Diabetes
Effect of Resveratrol on Insulin Sensitivity and Metabolic Profile in Type 2 Diabetics
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in type 2 diabetic patients.
As a secondary objective the investigators want to investigate whether the improved insulin sensitivity can be attributed to improved muscle mitochondrial oxidative capacity and a reduced intrahepatic and cardiac lipid content.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Limburg
-
Maastricht, Limburg, Nederland, 6200MD
- Maastricht University Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male sex
- Age: 40-70 years
- Body fat percentage > 25, BMI 27-35 kg/m2
- Diagnosed with type 2 diabetes at least one year before the start of the study
- Well-controlled type 2 diabetics: HBA1C < 8.0%
- Oral glucose lowering medication (metformin only or in combination with sulfonylurea agents)
Sedentary
- Not more than 2 hours of sports a week
- No active job that requires strenuous physical activity
- Stable dietary habits
- Willingness to abstain from resveratrol-containing food products
Exclusion Criteria:
- Unstable body weight (weight gain or loss > 3kg in the last three months)
- Total body fat percentage < 25%
- Hemoglobin < 7.8 mmol/l
- Use of anticoagulants
- Engagement in programmed exercise > 2 hours total per week
- Impaired kidney and/or hepatic function Creatinine 50-100 umol/L Liver enzymes, within 2 times of normal range of laboratory standard (ASAT < 60 U/L, ALAT < 70 U/L, Billi <40 umol/L, gamma-GT < 80 U/L)
- No diabetes related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy
- Insulin dependent Diabetic subjects
- Any medical condition except type 2 diabetes mellitus requiring treatment and/or medication use except metformin only or in combination with sulfonylurea agents
- Intake of dietary supplements except multivitamins and minerals
- Current alcohol consumption > 20 grams/day
- Subjects who don't want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study.
- Participation in another biomedical study within 1 month before the first screening visit
Any contraindication to MRI scanning. These contra-indications include patients with following devices:
- Central nervous system aneurysm clip
- Implanted neural stimulator
- Implanted cardiac pacemaker of defibrillator
- Cochlear implant
- Insulin pump
- Or metal containing corpora aliena in the eye or brains
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: placebo
A placebo will be given for 30 days, twice daily.
One pill will be provided with lunch and the other pill will be provided with dinner.
|
A placebo will given for 30 days, twice daily.
One pill will be provided with lunch, and the other pill will be provided with dinner.
|
Aktiv komparator: resveratrol
resveratrol will be given for 30 days, twice daily.
One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner.
So in total 150 mg/day of resveratrol will be given.
|
resveratrol will be given for 30 days, twice daily.
One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner.
So in total a dose of 150 mg/day will be given.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
insulin sensitivity (overall, muscle- and liver specific)
Tidsramme: 30 days after supplementation
|
30 days after supplementation
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
muscle mitochondrial oxidative capacity
Tidsramme: 30 days after supplementation
|
30 days after supplementation
|
intramyocellular lipid content
Tidsramme: 30 days after supplementation
|
30 days after supplementation
|
intrahepatic lipid content
Tidsramme: 30 days after supplementation
|
30 days after supplementation
|
intracardiac lipid content
Tidsramme: 30 days after supplementation
|
30 days after supplementation
|
heart function
Tidsramme: 30 days after supplementation
|
30 days after supplementation
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Silvie Timmers, PhD, Human Biology, Maastricht University Medical Center
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 11-3-092
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkjentHER-2 genamplifikasjon | HER-2 Protein Overekspresjon
-
The University of Tennessee, KnoxvilleFullførtMattelærere (2.–8. klasse) | Mattestudenter (2.–8. klasse)Forente stater
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkjentSolid svulst | HER-2 genamplifikasjon | HER2 genmutasjon | HER-2 Protein OverekspresjonKina
-
PowderMedFullført
-
Argorna Pharmaceuticals Co., LTDFullført
-
Argorna Pharmaceuticals Co., LTDFullført
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Aktiv, ikke rekrutterende
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Aktiv, ikke rekrutterende
-
Arcturus Therapeutics, Inc.Avsluttet
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsFullført
Kliniske studier på placebo
-
SamA Pharmaceutical Co., LtdUkjentAkutt bronkitt | Akutt øvre luftveisinfeksjonKorea, Republikken
-
National Institute on Drug Abuse (NIDA)FullførtCannabisbrukForente stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyFullførtMannlige personer med type II diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedFullførtFarmakokinetikk | SikkerhetsproblemerStorbritannia
-
Regado Biosciences, Inc.FullførtFrivillig friskForente stater
-
Texas A&M UniversityNutraboltFullførtGlucose and Insulin Response
-
Longeveron Inc.AvsluttetHypoplastisk venstre hjertesyndromForente stater
-
ItalfarmacoFullførtBecker muskeldystrofiNederland, Italia
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Fullført